RECEIVED
SEP 0 5 2003
TECH CENTER 1600/290

I WREBY CERTIFY THAT THIS CORRESPONDENCE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON THE DATE INDICATED BELOW.

Kristin L. Apuzzo

(TYPED OR PRINTED NAME OF PERSON MAILING

PAPER OR FEE)

BUSUL LYNGO (BIGNATURE OF PERSON MAILING PAPER OR FEE)

August 29, 2003

(DATE OF SIGNATURE)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:  Richard Leslie Edelson	)
Carole Berger Douglas Hanlon	) Group Art Unit: 1636
on METHODS FOR INDUCING THE	)
ON METHODS FOR INDUCING THE DIFFERENTIATION OF MONOCYTES INTO	)
FUNCTIONAL DENDRITIC CELLS AND	)
IMMUNOTHERAPEUTIC COMPOSITIONS	)
INCLUDING SUCH DENDRITIC CELLS	)
Serial Number: 10/066,021	)
Filed On: January 31, 2002	) (Docket No. 270425,0008

Hartford, Connecticut, August 29, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement mailed July 29, 2003, Applicant hereby elects, with traverse, Group I (claims 1-15 and 22) for initial prosecution on the merits.

Applicant respectfully submits that a restriction requirement between patentably distinct inventions is proper only when there is a serious burden on the Patent

Office to examine all of the claims in a single application even when it appears that appropriate reasons exist for a restriction requirement. M.P.E.P. §803. To avoid unnecessary delay and expense to Applicant and duplicative examination by the patent Office, Applicant respectfully requests that the above policy be applied in the present application because the subject matter of the pending claims is sufficiently related.

Group I is directed to methods for producing functional antigen presenting dendritic cells by inducing monocyte differentiation into dendritic cells and incubating the dendritic cells in the presence of apoptotic disease effector agents. Group II is directed to methods for producing functional antigen presenting dendritic cells by inducing monocyte differentiation into dendritic cells and incubating the dendritic cells in the presence of disease effector agents coated with monoclonal antibodies having a free Fc segment, wherein the disease effector agents may have been rendered apoptotic. Applicant believes that a thorough search for the subject matter of any one claim of the above-captioned patent application would overlap with a search for the subject matter of the remaining claims such that a search of the entire application can be made without serious burden. Therefore, Applicant respectfully requests reconsideration and withdrawal of the restriction requirement.

3

No fee is believed to be required in connection with this paper; however, if an additional fee is required, or otherwise if necessary to cover any deficiency in fees already paid, authorization is hereby given to charge our deposit account no. 50-1631.

If there are any questions, or if any additional material or information is required, please call the undersigned at the telephone number below.

Respectfully submitted,

Dated: August 29, 2003

Fric F Grondahl

Attorney for Applicant Registration No. 46,741

PTO Correspondence Address:

Cummings & Lockwood Granite Square 700 State Street P.O. Box 1960 New Haven, CT 06509-1960 Phone: (860) 275-6704

Phone: (860) 275-6704 Fax: (860) 560-5987

.HrtLib1:391734.1 08/29/03